Dr. Reddy's

Dr. Reddy's launched Toripalimab in India on Nov 28, 2024, an immune oncology drug for rare head and neck cancer. India is the third country to access this next-gen PD-1 inhibitor. Dr. Reddy's R&D increased at 8% CAGR over FY19-FY24, with FY24 R&D growth at 18%. Revenues grew 17% YoY to INR80.2bn in 2QFY25, driven by Global Generics and new product launches. Dr. Reddy's trades at a P/E of 18.0x, lower than peers Cipla and Zydus.

India's organized pharma retail market grew 11% in November, led by derma, cardiac, and respiratory drugs. Foracort topped sales at Rs 82 crore, followed by Augmentin and Glycomet GP. Urology, derma, cardiac, and pain-relief segments grew 18%, 16%, 13%, and 13% respectively. Sun Pharma led with an 8% market share, while domestic companies slightly outpaced MNCs. The market is expected to grow in high single digits by 2025, driven by price increases and new launches, including GLP-1 drugs.

Subscribe to our newsletter & stay updated.

Explore Smartkarma's AI-augmented platform with a free Preview Pass to unlock research summaries, follow top analysts, receive personalized alerts, and access analytics and events. Join 55,000+ investors, including top global asset managers. Upgrade to paid plans later.

Dr. Reddy's and Senores Pharmaceuticals launch ivermectin tablets, 3 mg, the generic of Stromectol by Merck Sharp and Dohme. The market value for these tablets was $20 million for the 12 months ending September 2024.

Suspicious activity violating TipRanks' Terms of Use detected, including excessive page views or use of scraping tools. Account usually reactivates within 24 hours; contact support if still disabled.

Six generic drugmakers, including Dr. Reddy’s, Hetero, and Mylan, signed non-exclusive, royalty-free licensing agreements with Gilead to produce and market generic lenacapavir in 120 high-incidence countries. Lenacapavir, approved for treating multidrug-resistant HIV-1, is also under investigation for HIV prevention (PrEP). These agreements aim to expedite access to the drug in low- and lower-middle-income countries.

SEBI Chairperson Madhabi Puri Buch and her husband Dhaval Buch refute conflict of interest claims, detailing Dhaval's extensive qualifications and experience, and emphasizing transparency in their financial dealings, including consulting assignments and rental income.